Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

[1]  G. Plant,et al.  Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential , 2018, CNS Drugs.

[2]  G. Plant,et al.  Predictors of response to opicinumab in acute optic neuritis , 2018, Annals of clinical and translational neurology.

[3]  D. Arnold,et al.  Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension , 2018, The Lancet Neurology.

[4]  A. Ranger,et al.  Anti-LINGO-1 has no detectable immunomodulatory effects in preclinical and phase 1 studies , 2017, Neurology: Neuroimmunology & Neuroinflammation.

[5]  Theodore V. Tselios,et al.  Multiple Sclerosis: Immunopathology and Treatment Update , 2017, Brain sciences.

[6]  C. Henderson,et al.  LINGO-1 Regulates Oligodendrocyte Differentiation through the Cytoplasmic Gelsolin Signaling Pathway , 2017, The Journal of Neuroscience.

[7]  S. Galetta,et al.  Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial , 2017, The Lancet Neurology.

[8]  Jeffrey A. Cohen,et al.  The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis , 2017, Multiple sclerosis.

[9]  D. McTigue,et al.  A silver lining of neuroinflammation: Beneficial effects on myelination , 2016, Experimental Neurology.

[10]  H. Hartung,et al.  Pushing Forward: Remyelination as the New Frontier in CNS Diseases , 2016, Trends in Neurosciences.

[11]  Ludwig Kappos,et al.  Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial , 2016, The Lancet.

[12]  O. Ciccarelli,et al.  Nonconventional MRI and microstructural cerebral changes in multiple sclerosis , 2015, Nature Reviews Neurology.

[13]  Mike P. Wattjes,et al.  Remyelination therapy goes to trial for multiple sclerosis , 2014, Neurology: Neuroimmunology & Neuroinflammation.

[14]  David H. Miller,et al.  Imaging outcomes for trials of remyelination in multiple sclerosis , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[15]  S. Mi,et al.  Blocking LINGO-1 as a Therapy to Promote CNS Repair: From Concept to the Clinic , 2013, CNS Drugs.

[16]  R. Franklin,et al.  Rejuvenation of regeneration in the aging central nervous system. , 2012, Cell stem cell.

[17]  Christilyn P. Graff,et al.  Exposure Levels of Anti-LINGO-1 Li81 Antibody in the Central Nervous System and Dose-Efficacy Relationships in Rat Spinal Cord Remyelination Models after Systemic Administration , 2011, Journal of Pharmacology and Experimental Therapeutics.

[18]  G. Disanto,et al.  Heterogeneity in Multiple Sclerosis: Scratching the Surface of a Complex Disease , 2010, Autoimmune diseases.

[19]  A. Nazarali,et al.  Age-Related and Cuprizone-Induced Changes in Myelin and Transcription Factor Gene Expression and in Oligodendrocyte Cell Densities in the Rostral Corpus Callosum of Mice , 2010, Cellular and Molecular Neurobiology.

[20]  A. Chédotal,et al.  Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells , 2009, Annals of neurology.

[21]  D. Arnold,et al.  Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions , 2008, Annals of neurology.

[22]  Li Wang,et al.  LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis , 2007, Nature Medicine.

[23]  Elizabeth Fisher,et al.  Imaging correlates of axonal swelling in chronic multiple sclerosis brains , 2007, Annals of neurology.

[24]  J. Chan,et al.  NGF Regulates the Expression of Axonal LINGO-1 to Inhibit Oligodendrocyte Differentiation and Myelination , 2007, The Journal of Neuroscience.

[25]  Hans Lassmann,et al.  Remyelination is extensive in a subset of multiple sclerosis patients. , 2006, Brain : a journal of neurology.

[26]  B. Trapp,et al.  LINGO-1 negatively regulates myelination by oligodendrocytes , 2005, Nature Neuroscience.

[27]  J. Relton,et al.  LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex , 2004, Nature Neuroscience.

[28]  L. Jasmin,et al.  Remyelination within the CNS: Do Schwann Cells Pave the Way for Oligodendrocytes? , 2002, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[29]  B. Trapp,et al.  Differentiation and Death of Premyelinating Oligodendrocytes in Developing Rodent Brain , 1997, The Journal of cell biology.

[30]  E. Cho,et al.  Multiple sclerosis: Remyelination of nascent lesions: Remyelination of nascent lesions , 1993 .

[31]  G. Devries,et al.  Role of adult oligodendrocytes in remyelination after neural injury. , 1992, Journal of neurotrauma.